References

medalphabet

Медицинский алфавит

Medical alphabet

2078-56312949-2807

ООО «Альфмед»

medalphabet-247

Research Article

Статьи

Андрогенетическое поредение волос по женскому типу: обзор клинической картины, патофизиологии и зарубежного опыта лечения

Female hair loss: review of clinical picture, pathophysiology and foreign experience of treatment

Новоселов

В. С.

Novosyolov

V. S.

noemail@neicon.ru

Ковалева

А. А.

Kovalyova

A. A.

noemail@neicon.ru

ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский университет)» Минздрава РоссииRussian FederationФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава РоссииRussian Federation

2017

09072017

221

Больница — все для ЛПУ

2332

2017

Новоселов В.С., Ковалева А.А.

Novosyolov V.S., Kovalyova A.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-alphabet.com/jour/article/view/247

Женский тип потери волос или женская андрогенная алопеция является основной причиной выпадения волос у взрослых женщин и оказывает значительное влияние на качество жизни пациенток. Она представляет собой безрубцовую алопецию с мультифакториальной этиологией, поражающую в большинстве случаев женщин в постменопаузе и характеризуется постепенной миниатюризацией фолликулов, приводя к последующему снижению количества волос. Несмотря на высокую частоту заболевания и значимость ее психологического влияния, патогенез данного процесса еще не до конца изучен, поскольку включает как генетические и гормональные, так и экологические факторы. Кроме того, ответ пациентов на лечение довольно вариабелен. Цель лечения: уменьшение выпадения волос и стимуляция роста новых волос. В настоящее время имеются множество методов терапии, однако остается открытым вопрос, какой из них является наиболее эффективным. Раннее начало терапии и комбинация различных способов лечения дают наилучший результат.

Female type of hair loss or female androgenic alopecia is the main cause of hair loss in adult women. It has a significant impact on the quality of life of these patients. It is a non-scarified alopecia with a multifactorial etiology, affecting in most cases postmenopausal women and is characterized by a gradual miniaturization of the follicles, leading to the subsequent increase in the amount of hair. Despite the high frequency of the disease and the importance of its psychological impact, the pathogenesis of this process has not yet been fully understood, since it includes both genetic and hormonal, and environmental factors. In addition, patients’ response to treatment is quite variable. The goal of the treatment is to reduce hair loss and stimulate growth of new hair. Currently, there are many therapies, however, the question remains open, which of them is the most effective. Early start of therapy and combining different treatments give the best result.

алопецияандрогеныженский тип потери волосминоксидилфинастерид

alopeciaandrogensfemale hair loss typeminoxidilfinasteride

References1

Jmrezende.com.br [Internet]. Rezende JM. Linguagem médica: Alopécia, alopecia. 2011. [acesso 11 nov 2013]. Disponivelem: http://www.jmrezende.com.br/alopecia.htm.

Academia.org.br [Internet]. Busca no vocabulârio. Academia Brasileira de Letras, 2009. [acesso 11 nov 2013]. Disponivel em: http://www.academia.org.br/abl/cgi/cgilua.exe/sys/start.htm?sid=23.

Decs.bvs.br [Internet]. Descritores em ciências da saöde. Biblioteca Virtual em Saöde, 2013. [acesso 11 nov 2013]. Disponivel em: http://decs.bvs.br/cgi-bin/wxis1660.exe/decsserver/.

Plenck J.J. Doctrina de Morbis Cutaneis. Qua hi morbi in suas classes, genera et species redingtur. Vienna: Van Overbeke; 1776.

Sinclair R. Winding the clock back on female androgenetic alopecia. Br J Dermatol. 2012; 166: 1157-8.

Sulzberger M.B., Witten V.H., Kopf A.W. Diffuse alopecia in women. Its unexplained apparent increase in incidence. Arch Dermatol. 1960; 81: 556-60.

Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977; 97: 247-54.

Hamilton J.B. Male hormone stimulation is prerequisite and an incitant in common baldness. Am J Anat. 1942; 71: 451-80.

Norwood O.T. Male pattern baldness: classification and incidence. South Med J. 1975; 68: 1359-65.

Olsen E.A. Female pattern hair loss. J Am Acad Dermatol. 2002; 45: S70-80.

Shapiro J. Clinical practice. Hair loss in women. N Engl J Med. 2007; 357: 1620-30.

Sociedade Brasileira de Dermatologia SBD. Perfil nosolôgico das consultas dermatolôgicas no Brasil. An Bras Dermatol 2006; 81: 545-54.

Tosti A., Piraccini B.M. Androgenetic alopecia. In: Tosti A., Piraccini B.M., editors. Diagnosis and treatment of hair disorders: An evidence based atlas London: Taylor and Francis; 2006. P. 45-56.

Pereira J.M. Propedêutica das doenças dos cabelos e do couro cabeludo. Rio de Janeiro: Atheneu; 2001.

Pereira J.M. Alopecia Androgenética (CaMcie) na Mulher. 2. São Paulo: Di Livros; 2007.

Norwood O.T. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg. 2001; 27: 53-4.

Birch M.P., Messenger J.F., Messenger A.G. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001; 144: 297-304.

Gan D.C., Sinclair R.D. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005; 10: 184-9.

Paik J.H., Yoon J.B., Sim W.Y., Kim B.S., Kim N.I. The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol. 2001; 145: 95-9.

Wang T.L., Zhou C., Shen Y.W., Wang X.Y., Ding X.L., Tian S., et al. Prevalence of androgenetic alopecia in China: a community-based study in six cities. Br J Dermatol. 2010; 162: 843-7.

Su L.H., Chen L.S., Chen H.H. Factors associated with female pattern hair loss and its prevalence in Taiwanese women: a community-based survey. J Am Acad Dermatol. 2013; 69: 556-77.

Lee A.T., Zane L.T. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol. 2007; 8: 201-19.

Tosti A., Pazzaglia M., Soli M., Rossi A., Rebora A., Atzori L., et al. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia. Arch Dermatol. 2004; 140: 857-8.

Kim B.J., Kim J.Y., Eun H.C., Kwon O.S., Kim M.N., Ro B.I. Androgenetic alopecia in adolescents: a report of 43 cases. J Dermatol. 2006; 33: 696-9.

Madnani N., Khan K., Chauhan P., Parmar G. Polycystic ovarian syndrome. Indian J Dermatol Venereol Leprol. 2013; 79: 310-21.

Dalamaga M., Papadavid E., Basios G., Vaggopoulos V., Rigopoulos D., Kassanos D., et al. Ovarian SAHA syndrome is associated with a more insulin-resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: A prospective controlled study. J Am Acad Dermatol. 2013; 69: 922-30.

Ding E.L., Song Y., Manson J.E., Hunter D.J., Lee C.C., Rifai N., et al. Sex hormonebinding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 2009; 361: 1152-63.

Arias-Santiago S., Gutiérrez-Salmerón M.T., Buendía-Eisman A., Girôn-Prieto M.S., Naranjo-Sintes R. Sex hormone-binding globulin and risk of hyperglycemia in patients with androgenetic alopecia. J Am Acad Dermatol. 2011; 65: 48-53.

Yi S.M., Son S.W., Lee K.G., Kim S.H., Lee S.K., Cho E.R., et al. Gender-specific association of androgenetic alopecia with metabolic syndrome in a middle-aged Korean population. Br J Dermatol. 2012; 167: 306-13.

Abdel Fattah N.S., Darwish Y.W. Androgenetic alopecia and insulin resistance: are they truly associated? Int J Dermatol. 2011; 50: 417-22.

Su L.H., Chen L.S., Lin S.C., Chen H.H. Association of androgenetic alopecia with mortality from diabetes mellitus and heart disease. JAMA Dermatol. 2013; 149: 601-6.

Mansouri P., Mortazavi M., Eslami M., Mazinani M. Androgenetic alopecia and coronary artery disease in women. Dermatol Online J. 2005; 11: 2.

Arias-Santiago S., Gutiérrez-Salmerôn M.T., Castellote-Caballero L., Buendía-Eisman A., Naranjo-Sintes R. Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study. J Am Acad Dermatol. 2010; 63: 420-9.

Messenger A.G. Hair through the female life cycle. Br J Dermatol. 2011; 165: 2-6.

Paus R., Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999; 341: 491-7.

Cotsarelis G., Millar S.E. Towards a molecular understanding of hair loss and its treatment. Trends Mol Med. 2001; 7: 293-301.

Rebora A., Guarrera M. Kenogen. A new phase of the hair cycle? Dermatology. 2002; 205: 108-10.

Garza L.A., Liu Y., Yang Z., Alagesan B., Lawson J.A., Norberg S.M., et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012; 4: 126ra34.

Trueb R.M. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002;37: 981-90.

Milner Y., Sudnik J., Filippi M., Kizoulis M., Kashgarian M., Stenn K. Exogen, shedding phase of the hair growth cycle: characterization of a mouse model. J Invest Dermatol. 2002; 119: 639-44.

Kishimoto J., Ehama R., Ge Y., Kobayashi T., Nishiyama T., Detmar M., Burgeson R.E. In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. Am J Pathol. 2000; 157: 103-10.

Kishimoto J., Burgeson R.E., Morgan B.A. Wnt signaling maintains the hair-inducing activity of the dermal papilla. Genes Dev. 2000; 14: 1181-5.

Stenn K.S., Paus R. Controls of hair follicle cycling. Physiol Rev. 2001; 81: 449-94.

Randall V.A., Jenner T.J., Hibberts N.A., De Oliveira I.O., Vafaee T. Stem cell factor/cKit signalling in normal and androgenetic alopecia hair follicles. J Endocrinol. 2008; 197: 11-23.

Hébert J.M., Rosenquist T., Götz J., Martin G.R. FGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations. Cell. 1994; 78: 1017-25.

Sawaya M.E., Blume-Peytavi U., Mullins D.L., Nusbaum B.P., Whiting D., Nicholson D.W., et al. Effects of finasteride on apoptosis and regulation of the human hair cycle. J Cutan Med Surg. 2002; 6: 1-9.

Botchkareva N.V., Kahn M., Ahluwalia G., Shander D. Survivin in the human hair follicle. J Invest Dermatol. 2007; 127: 479-82.

Botchkareva N.V., Ahluwalia G., Shander D. Apoptosis in the hair follicle. J Invest Dermatol. 2007;127: 479-82.

van Scott E.J., Ekel T.M. Geometric Relationships Between the Matrix of the Hair Bulb and its Dermal Papilla in Normal and Alopecic Scalp1. J Invest Dermatol. 1958; 31: 281-7.

Whiting D.A. Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J Am Acad Dermatol. 2001; 45: S81-6.

Whiting D.A. Advances in the treatment of male androgenetic alopecia: a brief review of finasteride studies. Eur J Dermatol. 2001; 11: 332-4.

Jahoda C.A. Cellular and developmental aspects of androgenetic alopecia. Exp Dermatol. 1998; 7: 235-48.

Seiberg M., Wisniewski S., Cauwenbergh G., Shapiro S.S. Trypsin-induced follicular papilla apoptosis results in delayed hair growth and pigmentation. Dev Dyn. 1997; 208: 553-64.

Randall V.A. Androgens and hair growth. Dermatol Ther. 2008; 21: 314-28.

Imperato-McGinley J., Guerrero L., Gautier T., Peterson R.E. Steroid 5a-reductase deficiency in man: an inherited form of male pseudohermaphroditism Science. 1974; 186: 1213-5.

Kaufman K.D. Androgens and alopecia. Mol Cell Endocrinol. 2002; 198: 89-95.

Kitagawa T., Matsuda K., Inui S., Takenaka H., Katoh N., Itami S., et al. Keratinocyte growth inhibition through the modification of Wnt signaling by androgen in balding dermal papilla cells. J Clin Endocrinol Metab. 2009; 94: 1288-94.

Zimber M.P.1, Ziering C., Zeigler F., Hubka M., Mansbridge J.N., Baumgartner M., et al. Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase

clinical trial. J Drugs Dermatol. 2011; 10: 1308-12.

Kaufman K.D., Olsen E.A., Whiting D., Savin R., DeVillez R., Bergfeld W., et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998; 39: 578-89.

Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002; 12: 38-49.

Yeon J.H., Jung J.Y., Choi J.W., Kim B.J., Youn S.W., Park K.C., 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol. 2011; 25: 211-I.

Iorizzo M., Vincenzi C., Voudouris S., Piraccini B.M., Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006; 142: 298-302.

Gupta A.K., Charrette A. The efficacy and safety of 5alpha-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatolog Treat. 2014; 25: 156-61.

Eun H.C., Kwon O.S., Yeon J.H., Shin H.S., Kim B.Y., Ro B.I., et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010; 63: 252-8.

Olszewska M., Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol. 2005; 4: 637-40.

Yip L., Rufaut N., Sinclair R.: Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol 2011; 52: 81-88.

Sawaya M.E., Price V.H.: Different levels of 5 alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997; 109: 296-300.

Niijama S., Happle R., Hoffmann R.: Influence of estrogens on the androgen metabolism in different subunits of human hair follicles. Eur J Dermatol 2001; 11: 195-198.

Conrad F., Paus R.: Estrogens and the hair follicle. J Dtsch Dermatol Ges 2004; 2: 412-423.

Mirmirani P.: Hormonal changes in menopause: do they contribute to a ‘midlife hair crisis’ in women? Br J Dermatol 2011; 165 (suppl. 3): 7-11.

Muallem M.M., Rubeiz N.G.: Physiological and biological skin changes in pregnancy. Clin Dermatol 2006; 24: 80-83.

Georgala S., Katoulis A.C., Georgala C., Moussatou V., Bozi E., Stavrianeas N.G.: Topical estrogen therapy for androgenetic alopecia in menopausal females. Dermatology 2004; 208: 178-189.

Yip L., Zaloumis S., Irwin D., Severi G., Hopper J., Giles G., Harrap S., Sinclair R., Ellis J.: Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol 2009; 161: 289-294.

Atanaskova Mesinkovska N., Bergfeld W.F.: Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment. Dermatol Clin 2013; 31: 119-127.

Mahé Y.F., Michelet J.F., Billoni N., Jarrousse F., Buan B., Commo S., et al. Androgenetic alopecia and microinflammation. Int J Dermatol. 2000; 39: 576-84.

Stefanato C.M. Histopathology of alopecia: a clinicopathological approach to diagnosis. Histopathology. 2010; 56: 24-38.

Whiting D.A. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol. 1993; 28: 755-63.

Nyholt D.R., Gillespie N.A., Heath A.C., Martin N.G. Genetic basis of male pattern baldness. J Invest Dermatol. 2003; 121: 1561-4.

Bergfeld W.F. Androgenetic alopecia: an autosomal dominant disorder. Am J Med. 1995; 98: 95S-98S.

Yazdan P. Update on the genetics of androgenetic alopecia, female pattern hair loss, and alopecia areata: implications for molecular diagnostic testing. Semin Cutan Med Surg. 2012; 31: 258-66.

Lee R., Chang S.Y., Trinh H., Tu Y., White A.C., Davies B.S., et al. Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes. Hum Mol Genet. 2010; 19: 1603-17.

Ellis J.A., Stebbing M., Harrap S.B. Genetic analysis of male pattern baldness and the 5alpha-reduc-tase genes. J Invest Dermatol. 1998; 110: 849-53.

Birch M.P., Messenger A.G. Genetic factors predispose to balding and non-balding in men. Eur J Dermatol. 2001; 11: 309-14. e-mail: medalfavit@mail.ru Медицинский алфавит № 21 / 2017, том № 2, Больница - все для ЛПУ

Ellis J.A., Harrap S.B. The genetics of androgenetic alopecia. Clin Dermatol Clin Dermatol. 2001; 19: 149-54.

Ellis J.A., Stebbing M., Harrap S.B. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol. 2001; 116: 452-5.

el-Samahy M.H., Shaheen M.A., Saddik D.E., Abdel-Fattah N.S., el-Sawi M.A., Mahran M.Z., et al. Evaluation of androgen receptor gene as a candidate gene in female androgenetic alopecia. Int J Dermatol. 2009; 48: 584-7.

Sawaya M.E., Shalita A.R. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg. 1998; 3: 9-15.

Calvo R.M., Asuncion M., Sancho J., San Millân J.L., Escobar-Morreale H.F. The role of the CAG repeat polymorphism in the androgen receptor gene and of skewed X-chromosome inactivation, in the pathogenesis of hirsutism. J Clin Endocrinol Metab. 2000; 85: 1735-40.

Li R., Brockschmidt F.F., Kiefer A.K., Stefansson H., Nyholt D.R., Song K., et al. Six novel susceptibility Loci for early-onset androgenetic alopecia and their unexpected association with common diseases. PLoS Genet. 2012; 8: e1002746.

Redler S., Dobson K., Drichel D., Heilmann S., Wolf S., Brockschmidt F.F., et al. Investigation of six novel susceptibility loci for male androgenetic alopecia in women with female pattern hair loss. J Dermatol Sci. 2013; 72: 186-8.

Heilmann S., Kiefer A.K., Fricker N., Drichel D., Hillmer A.M., Herold C., et al. Androgenetic alopecia: identification of four genetic risk loci and evidence for the contribution of WNT signaling to its etiology. J Invest Dermatol. 2013; 133: 1489-96.

Nuwaihyd R., Redler S., Heilmann S., Drichel D., Wolf S., Birch P., et al. Investigation of four novel male androgenetic alopecia susceptibility loci: no association with female pattern hair loss. Arch Dermatol Res. 2014; 306: 413-8.

Gatherwright J., Liu M.T., Gliniak C., Totonchi A., Guyuron B. The contribution of endogenous and exogenous factors to female alopecia: a study of identical twins. Plast Reconstr Surg. 2012; 130: 1219-26.

Blume-Peytavi U., Blumeyer A., Tosti A., Finner A., Marmol V., Trakatelli M., et al. S 1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol. 2011; 164: 5-15.

Sinclair R., Wewerinke M., Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005; 152: 466-73.

Olsen E.A. The midline part an important physical clue to the clinical diagnosis of androgenetic alopecia in women. J Am Acad Dermatol. 1999; 40: 106-9.

Olsen E.A. Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss. J Am Acad Dermatol. 2003; 48: 253-62.

Hamilton J.B. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. 1951; 53: 708-28.

100

Lee W.S., Oh Y., Ji J.H., Park J.K., Kim do W., Sim W.Y., et al. Analysis of familial factors using the basic and specific (BASP) classification in Korean patients with androgenetic alopecia. J Am Acad Dermatol. 2011; 65: 40-7.

101

Lee W.S., Lee H.J., Choi G.S., Cheong W.K., Chow S.K., Gabriel M.T., et al. Guidelines for management of androgenetic alopecia based on BASP classification - the Asian Consensus Committee guideline. J Eur Acad Dermatol Venereol. 2013; 27: 1026-34.

102

Lee W.S., Ro B.I., Hong S.P., Bak H., Sim W.Y., Kim do W., et al. A new classification of pattern hair loss that is universal for men and women: basic and specific (BASP) classification. J Am Acad Dermatol. 2007; 57: 37-46.

103

Kantor J., Kessler L.J., Brooks D.G., Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol. 2003; 121: 985-8.

104

Rushton D.H., Ramsay I.D. The importance of adequate serum ferritin levels during oral cypro-terone acetate and ethinyl oestradiol treatment of diffuse androgendependent alopecia in women. Clin Endocrinol (Oxf). 1992; 36: 421-7.

105

Trost L.B., Bergfeld W.F., Calogeras E. The diagnosis and treatment of iron deficiency and its potentialrelationship to hair loss. J Am Acad Dermatol. 2006; 54: 824-44.

106

Futterweit W., Dunaif A., Yeh H.C., Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol. 1988; 19: 831-6.

107

Freinkel R.K., Freinkel N. Hair growth and alopecia in hypothyroidism. Arch Dermatol. 1972; 106: 349-52.

108

Rasheed H., Mahgoub D., Hegazy R., El-Komy M., Abdel Hay R., Hamid M.A., et al. Serum ferritin and vitamin d in female hair loss: do they play a role? Skin Pharmacol Physiol. 2013; 26: 101-7.

109

Amor K.T., Rashid R.M., Mirmirani P. Does D matter? The role of vitamin D in hair disorders and hair follicle cycling. Dermatol Online J. 2010; 16: 3.

110

Malloy P.J., Feldman D. The role of vitamin D receptor mutations in the development of alopecia. Mol Cell Endocrinol. 2011; 347: 90-6.

111

Blumeyer A., Tosti A., Messenger A., Reygagne P., del Marmol V., Spuls P.I., Trakatelli M., Finner A., Kiesewetter F., Trüeb R., Rzany B., Blume-Peytavi U.; European Dermatology Forum (EDF). Evidence-based (S 3) guideline for the treatment of androgenetic alopecia in women and men. J Dtsch Dermatol Ges 2011; 9 (suppl6): S1-S57.

112

Rogers N.E., Avram M.R.: Medical treatments for male and female pattern hair loss. J Am Acad Dermatol 2008; 59: 547-566.

113

Messenger A.G., Rundegren J.: Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004; 150: 186-194.

114

Haber R.S.: Pharmacologic management of pattern hair loss. Facial Plast Surg Clin North Am 2004; 12: 181-189.

115

Whiting D.A., Jacobson C.: Treatment of female androgenetic alopecia with minoxidil 2%. Int J Dermatol 1992; 31: 800-804.

116

Jacobs J.P., Szpunar C.A., Warmer M.L.: Use of topical minoxidil therapy for androgenetic alopecia in women. Int J Dermatol 1993; 32: 758-762.

117

Tsuboi R., Tanaka T., Nishikawa T., Ueki R., Yamada H., Katsuoka K., Ogawa H., Takeda K.: A randomized, placebo-controlled trial of 1 % topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women, Eur J Dermatol 2007; 17: 37-44.

118

Olsen E., Whiting D., Bergfeld W., Miller J., Hordinsky M., Wanser R., Zhang P., Kohut B: A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5 % minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007; 57: 767-774.

119

Lucky A.W., Picquadio D.J., Ditre C.M., Dunlap F., Kantor I., Pandya A.G., Savin R.C., Tharp M.D.: A randomized, placebocontrolled trial of 5 and 2 % topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004; 50: 541-553.

120

Blume-Peytavi U., Hillmann K., Dietz E., Canfield D., Garcia Bartels N.: A randomized, single-blind trial of 5 % minoxidil foam once daily versus 2 % minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol2011; 65: 1126-1134.

121

Leyden J., Dunlap F., Miller B., Winters P., Lebwohl M., Hecker D., Kraus S., Baldwin H., Shalita A., Draelos Z., Markou M., Thiboutot D., Rapaport M., Kang S., Kelly T., Pariser D., Webster G., Hordinsky M., Rietschel R., Katz H.I., Terranella L., Best S., Round E., Waldstreicher J.: Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999; 40: 930-937.

122

Price V.H., Roberts J.L., Hordinsky M., Olsen E.A., Savin R., Bergfeld W., Fiedler V., Lucky A., Whiting D.A., Pappas F., Culbertson J., Kotey P., Meehan A., Waldstreicher J.: Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000; 43: 768-776.

123

Shum K., Cullen D., Messenger A.: Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol 2002; 47: 733-739.

124

Yeon J.H., Jung J.Y., Choi J.W., Kim B.J., Youn S.W., Park K.C., Huh C.H.: 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol 2011; 25: 211-214.

125

Iorizzo M., Vincenzi C., Voudouris S., Piraccini B.M., Tosti A.: Finasteride treatment of female pattern hair loss. Arch Dermatol 2006; 142: 298-302.

126

Hajheydari Z., Akbari J., Saeedi M., Shokoohi L.: Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol 2009; 75: 47-51.

127

Olsen E.A., Hordinsky M., Whiting D., Stough D., Hobbs S., Ellis M.L., Wilson T., Rittmaster R.S.; Dutasteride Alopecia Research Team. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006; 55: 1014-1023.

128

Olszewska M., Rudnicka L.: Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 2005; 4: 637-640.

129

Moftah N., Moftah N., Abd-Elaziz G., Ahmed N., Hamed Y., Ghannam B., Ibrahim M.: Mesotherapy using dutasteridecontaining preparation in treatment of female pattern hair loss: photographic, morphometric and ultrastructural evaluation. J Eur Acad Dermatol Venereol 2013; 27: 686-693.

130

Camacho-Martinez F.M.: Hair loss in women. Semin Cutan Med Surg 2009; 28: 19-32.

131

Hoedemaker C., van Egmond S., Sinclair R.: Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Australas J Dermatol 2007; 48: 43-45.

132

Sinclair R., Wewerinke M., Jolley D.: Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 2005; 152: 466-473.

133

Rogers N.E., Avram M.R.: Medical treatments for male and female pattern hair loss. J Am Acad Dermatol 2008; 59: 547-566.

134

Paradisi R., Porcu E., Fabbri R., Seracchioli R., Battaglia C., Venturoli S.: Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother 2011; 45: 469-575.

135

Gassmueler J., Hoffmann R., Webster A.: Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. Br J Dermatol 2008; 158: 109-115.

136

Levy L.L., Emer J.J.: Female pattern alopecia: current perspectives. Int J Womens Health 2013; 5: 541-556.

137

Cohen J.L.: Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-in-duced eyelash growth. Dermatol Surg 2010; 36: 1361-1371.

138

Blume-Peytavi U., Lönnfors S., Hillmann K., Garcia Bartels N.: A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latano-prost 0.1 % on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol 2012; 66: 794-800.

139

Hugo Perez B.S.: Ketoconazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Med Hypotheses 2004; 62: 112-115.

140

McElwee K.J., Shapiro J.S.: Promising therapies for treating and/or preventing androgenic alopecia. Skin Therapy Lett 2012; 17: 1-4.

141

Cucé L., Consuelo J.R., Régia C.R.P.: Celliu M.® GC: evaluation of a new natural active ingredient in 210 mg/ml topical solution, through scalp biopsy. Surg Cosmet Dermatol 2011; 3: 123-128.

142

Bernard B.A.: The human hair follicle, a bistable organ? Exp Dermatol 2012; 21: 401-403.

143

Finner A.M.: Nutrition and hair: deficiencies and supplements. Dermatol Clin 2013; 31: 167-172.

144

Rajput R.J.: Controversy: is there a role for adjuvants in the management of male pattern hair loss? J Cutan Aesthet Surg 2010; 3: 82-86.

145

Freund B., Schwartz M.: Treatment of male pattern baldness with botulinum toxin: a pilot study. Plast Reconstr Surg 2010; 126: 246e-248e.

The authors declare that there are no conflicts of interest present.